After five consecutive days of low-dose IL2 therapy, significant increases in lymphocyte subpopulations were seen in SLE patients with infection as effectively as seen in SLE patients without infection: T (p<0.001), B (p<0.001), CD8+ T (p<0.01), NK (p<0.001), Th1 (p<0.01), Treg (p<0.10). This increase in lymphocyte cell subpopulations was comparable to levels in healthy controls. The gene discussed is IL2; the disease is systemic lupus erythematosus.